ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Assessment of the Time to Therapeutic Tacrolimus Levels and the Incidence of Rejection in Heart Transplant Patients

M. Moaddab, L. Simpson, M. Rabourn

St.Luke's Episcopal Hospital, Houston, TX
Texas Heart Institute, Houston, TX

Meeting: 2013 American Transplant Congress

Abstract number: C1446

Related Abstracts
  • Effects of Various Therapeutic Levels of Tacrolimus on Early Post Transplant Outcomes
  • Effect of Intrapatient Variability and Mean Tacrolimus Levels in Renal Transplant Patients

Purpose: To assess the relationship between the time to achieve consecutive therapeutic tacrolimus levels and the incidence of rejection to optimize tacrolimus dosing in cardiac allograft recipients.

Methods: This was a retrospective observational study in heart transplant recipients from January 2010 – August 2012. Goal tacrolimus whole blood trough concentrations were 10 – 15 mcg/mL during the first 90 days post-transplantation. Patients were stratified according to the time to reach four consecutive therapeutic tacrolimus levels by the following time periods post-transplantation: less than or equal to 14 days, greater than 14 days, or never. The time to achieve consecutive therapeutic tacrolimus levels was correlated with the timing, type, and severity of rejection as evidenced on endomyocardial biopsy reports.

Results: Following standard basiliximab induction in 90 patients, tacrolimus was initiated at day 1 (0 – 4), median (range), post-transplantation. Achieving four consecutive therapeutic levels within 14 days post-cardiac transplantation was associated with the lowest incidence of grade 2R and 3R acute cellular rejection (1/8 versus 16/46 versus 13/36) and antibody-mediated rejection (1/8 versus 10/46 versus 4/36), respectively. All therapeutic four levels were equivalent to weight-based dosing recommendations at a median value of 0.07mg/kg/day.

Conclusions: Study results support weight-based tacrolimus dosing to achieve four consecutive therapeutic tacrolimus levels within 14 days post-cardiac transplantation to decrease the incidence of acute allograft rejection. This study is limited by observational design.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Moaddab M, Simpson L, Rabourn M. Assessment of the Time to Therapeutic Tacrolimus Levels and the Incidence of Rejection in Heart Transplant Patients [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/assessment-of-the-time-to-therapeutic-tacrolimus-levels-and-the-incidence-of-rejection-in-heart-transplant-patients/. Accessed January 19, 2021.

« Back to 2013 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.